Literature DB >> 8033373

Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.

L Chiovato1, F Santini, P Vitti, G Bendinelli, A Pinchera.   

Abstract

A patient with toxic nodular goitre is described in whom radioiodine (131I) therapy paradoxically induced typical Graves' disease. This patient had a goitre with two autonomously functioning nodules suppressing uptake by the remainder of the gland. Circulating thyroid peroxidase antibody indicated the coexistence of focal lymphocytic thyroiditis. Radioiodine therapy was followed by the development of severe and persistent Graves' hyperthyroidism associated with diffuse 131I uptake by the gland. A second administration of 131I produced a further worsening of hyperthyroidism, and the appearance of ophthalmopathy. TSH-receptor antibody and thyroid stimulating antibody were undetectable before 131I, appeared after the first administration of radioiodine, and showed a further increase after the second dose of 131I. We suggest that, in a patient genetically susceptible to thyroid autoimmunity, the release of TSH-receptor antigenic components from follicular cells damaged by radioiodine therapy triggered an autoimmune response to the TSH-receptor, thus turning a toxic nodular goitre into Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033373     DOI: 10.1111/j.1365-2265.1994.tb02516.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Radioiodine is an effective, inexpensive, and safe treatment for Graves' hyperthyroidism, its immunological effects must be taken into account.

Authors:  L Chiovato; R Rocchi; E Fiore
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

2.  Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay.

Authors:  Simone Dunkelmann; Ricarda Wolf; Annedore Koch; Christian Kittner; Peter Groth; Carl Schuemichen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

3.  Appearance of Graves' disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma.

Authors:  F Monzani; P Del Guerra; N Caraccio; A Casolaro; P V Lippolis; O Goletti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

4.  Toxic adenoma and papillary thyroid carcinoma in a patient with Graves' disease.

Authors:  T M Valenti; E Macchia; R Pisa; M L Bucalo; V Russo; I Colletti; V Compagno; V Abbadi; M Donatelli
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

5.  Graves' disease after percutaneous ethanol injection for the treatment of autonomous thyroid adenoma.

Authors:  G Verde
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

Review 6.  Role of genetic and non-genetic factors in the etiology of Graves' disease.

Authors:  M Marinò; F Latrofa; F Menconi; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2014-11-25       Impact factor: 4.256

7.  [Occurrence of immune hyperthyroidism after radioiodine therapy of autonomous goiter].

Authors:  C Hirsch; J L Spyra; H R Langhammer; C Laubenbacher; R Senekowitsch-Schmidtke; M Schwaiger
Journal:  Med Klin (Munich)       Date:  1997-03-15

8.  Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.

Authors:  B Nygaard; R A Metcalfe; J Phipps; A P Weetman; L Hegedüs
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

9.  Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.

Authors:  C Regalbuto; S Salamone; C Scollo; R Vigneri; V Pezzino
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

10.  Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.

Authors:  N Custro; A Ganci; V Scafidi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.